Ex Vivo Assay for Organ-Specific Cancer Cell Invasion

BackgroundMetastasis is the leading cause of cancer-related mortality, yet experimental models often fail to recapitulate the tissue-specific microenvironments that shape metastatic dissemination. While in vivo systems provide physiological relevance, they are poorly suited for mechanistic studies. Conversely, conventional in vitro assays lack the organ-specific extracellular matrix (ECM) context that critically regulates invasive behavior. There is therefore a need for accessible models that balance biological relevance with experimental feasibility. ResultsIn this study, we developed an ex vivo invasion platform based on mild detergent decellularization of mouse organs followed by vibratome slicing. This approach generates optically transparent lung, liver, and intestine ECM scaffolds that preserve native matrix architecture, mechanical properties, and retain biochemical hallmarks of their tissues of origin. Organ-derived matrices were integrated into standard microfluidic channels and analyzed using conventional fluorescence microscopy to enable quantitative assessment of cancer cell invasion. Benchmarking with breast cancer cell lines of defined invasive capacity, we could demonstrate the robustness and biological relevance of the system. Non-invasive MCF7 cells failed to infiltrate any organ scaffold, whereas highly invasive MDA-MB-231 cells exhibited pronounced organ-specific invasion. These cells preferentially invaded lung and liver ECM while showing minimal invasion of intestinal scaffolds, recapitulating clinically observed metastatic tropism. Quantitative invasion rates closely matched values previously reported in vivo using intravital microscopy. ConclusionsThis ex vivo organ-derived ECM platform provides a scalable, cost-effective, and experimentally accessible system to study ECM-driven determinants of metastatic invasion. By preserving tissue-specific matrix cues while reducing reliance on animal models, this approach provides a powerful tool to interrogate ECM-driven determinants of metastasis and to evaluate potential therapeutic interventions.